{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:52:29Z","timestamp":1791139949587,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T00:00:00Z","timestamp":1402876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Patients with rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) are at significantly higher risk of cardiovascular (<jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>) morbidity and mortality compared with the general population. Traditional <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> risk factors cannot explain the total excess of <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> morbidity and mortality in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. At present, it is not clear whether treatment with statins might be of benefit in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. The aim of the present systematic literature review is to summarize the published evidence concerning treatment with statins and its impact on <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> events in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review of studies on <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> and statins was carried out in the database PubMed. Search terms were \u2018simvastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> atorvastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> fluvastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> lovastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> pravastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> rosuvastatin <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> statin <jats:styled-content style=\"fixed-case\">AND<\/jats:styled-content> arthritis\u2019. Papers were included in this review when the reported outcome was on <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> events in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. After exclusion of the studies not fulfilling our inclusion criteria four studies were finally analyzed. The total number of <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients included in these studies was 4896.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Statins were associated with reduced <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> events and mortality in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> in primary prevention but not in secondary prevention. In secondary prevention after myocardial infarction (<jats:styled-content style=\"fixed-case\">MI<\/jats:styled-content>) there was no statistically significant difference between <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> or non\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients either receiving atorvastatin 80\u00a0mg or simvastatin 20\u201340\u00a0mg daily. Treatment with atorvastatin 80\u00a0mg led to a reduction in overall risk of <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> disease in both patients with and without inflammatory joint disease compared to patients receiving the conventional\/low\u2010dose statin treatment. Statin discontinuation in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients was associated with an increased risk of acute myocardial infarction or <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> mortality. Myalgia, diarrhoea, abdominal pain and nausea may be more frequent in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients than in controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The published evidence shows that in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients statin treatment appears to reduce <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> risk in primary prevention and that statin discontinuation is associated with an increased risk for <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> events. However, the significance of statin treatment in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients still remains unclear as only very little evidence has been published. Whether all <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients would benefit from treatment with statins still needs to be investigated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12415","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T23:17:33Z","timestamp":1402960653000},"page":"606-611","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?"],"prefix":"10.1111","volume":"17","author":[{"given":"Kathrin","family":"Danninger","sequence":"first","affiliation":[{"name":"Academic Research Unit 2nd Department of Medicine General Hospital Linz Linz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta C.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II SalzburgerLandeskliniken Paracelsus Medical University Salzburg Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Pieringer","sequence":"additional","affiliation":[{"name":"Academic Research Unit 2nd Department of Medicine General Hospital Linz Linz Austria"},{"name":"Paracelsus Medical University Salzburg Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq203"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_2_7_6_1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"4S Group","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.15.1446"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.044"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110318"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq295"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34524"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21643"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.21.2307"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201228"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000336"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113696"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:52:19Z","timestamp":1695545539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,16]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/1756-185X.12415"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12415","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,16]]},"assertion":[{"value":"2014-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}